Polypeptide CDPEP-135 and application thereof

Through the polypeptide CDPEP-135 screened from the sea frog poison gland sample, the treatment difficulties caused by drug resistance of Acinetobacter baumannii were solved, effective inhibition of multidrug-resistant strains and reduction of lung infections were achieved, and the patient showed that the Potential in clinical applications.

CN118909071APending Publication Date: 2024-11-08CHENGDU PEPBIO BIOMEDICAL CO LTD +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411160259.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The drug resistance problem of Acinetobacter baumannii has led to poor efficacy in traditional antibiotic treatment, and existing antibacterial drugs have limited effect on multidrug-resistant strains and lack effective treatment methods.

Method used

A polypeptide CDPEP-135 was developed. By conducting transcriptome sequencing and data analysis on sea frog virion samples, it was found that it had significant antibacterial activity against Acinetobacter baumannii and multidrug-resistant Acinetobacter baumannii, and constructed a recombinant plasmid and The polypeptide is purified by E. coli expression to prepare drugs against Acinetobacter baumannii.

Benefits of technology

The peptide CDPEP-135 shows strong inhibition of the activity of Acinetobacter baumannii, with a MIC value of 4-16 μg/ml, which can effectively reduce lung infection caused by Acinetobacter baumannii and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909071A_ABST
    Figure CN118909071A_ABST
Patent Text Reader

Abstract

The invention provides a polypeptide CDPEP-135 and application thereof, and belongs to the technical field of polypeptide drugs. The invention discovers that the doll-derived polypeptide CDPEP-135 is specifically A1) or A2) for the first time: A1) the amino acid sequence is shown as SEQ ID NO.1; a2) a fusion protein obtained by connecting a label to the N terminal or / and the C terminal of A1). The polypeptide CDPEP-135 has remarkable bacteriostatic activity on acinetobacter baumannii and multi-drug-resistant acinetobacter baumannii, can be used for preparing drugs for treating or preventing infection and diseases caused by the acinetobacter baumannii, and has a good clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of polypeptide drugs, and in particular to a polypeptide CDPEP-135 and an application thereof. Background Art

[0002] Acinetobacter baumannii ( Acinetobacter baumannii ) is a common clinical non-fermenting sugar, oxidase-negative Gram-negative bacillus, widely present in nature, and is one of the important pathogens causing nosocomial infections worldwide. It has strong adaptability, grows well in an environment of 20-30°C, has no special nutritional requirements, and has strong resistance to ultraviolet rays, chemical disinfection, and damp heat, and can even survive on dry inorganic surfaces for more than 27 days. As a conditional pathogen, Acinetobacter baumannii often colonizes on medical devices or equipment. Through invasive clinical operations such as endotracheal intubation, central venous catheterization, and urinary catheterization, it can cause pneumonia, bloodstream infection, urinary tract infection, etc., and even secondary meningitis, especially in ICU patients or people with low immunity due to long-term use of glucocorticoids. Acinetobacter baumannii can quickly develop resistance to multiple antibiotics by acquiring heterogeneous genetic material or spontaneous mutation. Due to the strong acquired drug resistance of Acinetobacter baumannii and the widespread and irregular use of antibiotics, its resistance rate has increased sharply in recent years. At the same time, pan-resistant or multidrug-resistant strains have emerged, making the clinical prevention and treatment of Acinetobacter baumannii infection a major challenge (Harding, CM, et al. Uncovering the mechanisms of Acinetobacter baumanniivirulence. 2018, Nat Rev Microbiol 16 (2), 91-102.; Mea, HJ, et al. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. 2021, Microbiol Res 247, 126722.).

[0003] Antimicrobial peptides (AMPs), also known as host defense peptides, are short, usually positively charged polypeptides that exist in organisms such as insects, plants, and animals, and are a very important defense system. Some AMPs have the ability to regulate the host defense system to indirectly kill microbial pathogens, but most AMPs can directly kill microbial pathogens. Compared with traditional antibiotics, AMPs have the advantages of broad antibacterial spectrum, low cytotoxicity, low resistance to drug resistance, strong heat resistance, good water solubility, low resistance to protease hydrolysis, and fast bactericidal speed. In addition, the functional characteristics of AMPs are also widely used, such as being able to fight viruses, bacteria, fungi and even tumor cells, which makes AMPs a very broad application prospect for antibacterial agents (Xuan, J., et al. Antimicrobial peptides for combating drug-resistantbacterial infections. 2023, Drug Resist Updat 68, 100954.).

[0004] Clinically, about 55% of Acinetobacter baumannii have become resistant to commonly used antibiotics such as ciprofloxacin, imipenem and ceftazidime, making it one of the most serious drug-resistant bacteria in clinical practice (Ibrahim, S. , et al. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. 2021, Mol BiolRep 48 (10), 6987-6998.). Faced with the increasingly serious problem of drug resistance in Acinetobacter baumannii, polymyxins (such as colistin) have once again become the last effective means of treating drug-resistant Acinetobacter baumannii infections, so there is an urgent need to develop new antimicrobial drugs. Summary of the invention

[0005] The purpose of the present invention is to provide a new polypeptide CDPEP-135 in view of the above-mentioned deficiencies of the prior art. The polypeptide is used for treating diseases caused by Acinetobacter baumannii infection.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions: The first object of the present invention is to provide a polypeptide CDPEP-135, wherein the polypeptide CDPEP-135 is specifically as follows A1) or A2): A1) The amino acid sequence is shown in SEQ ID NO.1; A2) A fusion protein obtained by connecting a tag to the N-terminus or / and C-terminus of A1): In order to facilitate the purification of the protein in A1), the tags shown in the following table can be connected to the amino terminus or carboxyl terminus of the protein composed of the amino acid sequence shown in SEQ ID No. 1 in the sequence table: Poly-Arg (RRRRR), Poly-His (HHHHHH), FLAG (DYKDDDK).

[0007] The second object of the present invention is to provide a biological material related to the above-mentioned polypeptide CDPEP-135, which is any one of the following B1) to B6): B1) encoding the polypeptide CDPEP-135 according to claim 1 B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant microorganism containing the nucleic acid molecule described in B1); B5) a recombinant microorganism containing the expression cassette described in B2); B6) A recombinant microorganism containing the recombinant vector described in B3).

[0008] The third object of the present invention is to provide the use of the above-mentioned biomaterial in the preparation of polypeptide CDPEP-135.

[0009] The fourth object of the present invention is to provide the use of the above-mentioned polypeptide CDPEP-135 or biomaterial in the preparation of drugs against Acinetobacter baumannii and / or multidrug-resistant Acinetobacter baumannii.

[0010] Further, the Acinetobacter baumannii is at least one of ATCC 27660, ATCC 6528, ATCC 25904, ATCC25923, ATCC 29213 and ATCC 49951; Furthermore, the multidrug-resistant Acinetobacter baumannii is a strain resistant to cephalosporins, carbapenems, and aminoglycosides.

[0011] The fifth object of the present invention is to provide a pharmaceutical composition, which comprises the above-mentioned polypeptide CDPEP-135 or a pharmaceutically acceptable salt thereof, and pharmaceutical excipients.

[0012] Furthermore, the polypeptide CDPEP-135 is the only effective active ingredient.

[0013] The sixth object of the present invention is the use of the above-mentioned polypeptide CDPEP-135 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing infections and diseases caused by Acinetobacter baumannii.

[0014] Further, the disease is one or more of ventilator-associated pneumonia, sepsis, urinary tract infection and wound infection. Acinetobacter baumannii is an important pathogen causing nosocomial infection, especially ventilator-associated pneumonia, sepsis, urinary tract infection, wound infection, etc.

[0015] The pharmaceutical excipients can be excipients widely used in the field of drug production. Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition, and can also provide a method to dissolve the active ingredient at a desired rate after the subject receives the administration, or promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipients can be inert fillers, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipients can include one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents and sweeteners.

[0016] The pharmaceutical composition of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or freeze-drying processes.

[0017] The pharmaceutical composition of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical composition of the present invention can also be a controlled release or delayed release dosage form (e.g., liposomes or microspheres). Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of preparations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories and lozenges.

[0018] The term "encoding nucleic acid molecule" as used in the present invention means a polynucleotide that directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon (such as ATG, GTG or TTG) and ends with a stop codon (such as TAA, TAG or TGA). The coding sequence may be genomic DNA, synthetic DNA or a combination thereof.

[0019] The term "expression" as used in the present invention includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0020] The term "recombinant vector" used in the present invention means a linear or circular DNA molecule comprising a polynucleotide encoding a polypeptide and operatively linked to a control sequence for its expression.

[0021] The term "host cell" as used in the present invention means any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is different from the parent cell due to mutations that occur during replication.

[0022] The term "pharmaceutically acceptable" as used in the present invention refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0023] The term "pharmaceutically acceptable salt" refers to a conventional salt-forming reaction in the art, for example, a salt formed by a chemical reaction between a base and an acid, such as: NH 3 + H 2 SO 4 →(NH 4 ) 2 SO 4 .

[0024] The salt can be an alkaline salt, an acidic salt, or a neutral salt. Alkaline salts produce hydroxide ions in water while acidic salts produce hydronium ions. The polypeptide CDPEP-135 can form a salt of the polypeptide polypeptide CDPEP-135 of the present invention with a cation or anion, respectively, between anionic groups or cationic groups. These groups can be located in the peptide portion of the polypeptide polypeptide CDPEP-135 of the present invention. The anionic group of the polypeptide polypeptide CDPEP-135 of the present invention can include a free carboxyl group of the peptide portion. The peptide portion generally includes a free carboxylic acid group at the C-terminus. The cationic group of the peptide portion is not limited in the present invention, including the free amino group at the N-terminus (if present) and any free amino group of the internal basic amino acid residues (such as Arg and Lys).

[0025] "Pharmaceutically acceptable acid addition salts" refers to those pharmaceutically acceptable salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from the aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic acid classes of organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, pamoic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid.

[0026] "Pharmaceutically acceptable base addition salts" refer to those pharmaceutically acceptable salts formed with organic or inorganic bases. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese and aluminum salts. Salts derived from pharmaceutically acceptable non-toxic bases include primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine and salts of polyamine resins.

[0027] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention uses sea frog ( Rana cancrivora ) was used as the research object. Through transcriptome sequencing, data analysis and peptide selection of venom gland samples, it was discovered for the first time that the peptide CDPEP-135 from sea frogs had significant antibacterial activity against both Acinetobacter baumannii and multidrug-resistant Acinetobacter baumannii.

[0028] (2) The present invention studies the antibacterial activity of the peptide CDPEP-135. The results show that the peptide CDPEP135 has a strong inhibitory activity against a variety of Acinetobacter baumannii, and its MIC value is 4-16 μg / ml.

[0029] (3) The present invention constructs a mouse lung infection model of Acinetobacter baumannii. The research results show that the peptide CDPEP135 effectively reduces lung infection caused by Acinetobacter baumannii and can be used to prepare drugs for treating or preventing infections and diseases caused by Acinetobacter baumannii, which has a good prospect for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is a diagram showing the effect of peptide CDPEP-135 on the microstructure of Acinetobacter baumannii; Figure 2 This is the evaluation result of the hemolytic activity of peptide CDPEP-135; Figure 3 This is a graph showing the therapeutic effect of peptide CDPEP135 on lung damage caused by drug-resistant Acinetobacter baumannii infection; Figure 4 This is a graph showing the effect of peptide CDPEP135 on the bacterial load of drug-resistant Acinetobacter baumannii in the lungs of mice; Figure 5 This figure shows the effect of peptide CDPEP135 on inflammatory cell infiltration caused by drug-resistant Acinetobacter baumannii infection. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solution and advantages of the present invention clearer, embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and cannot be understood as limiting the present invention.

[0032] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, usually according to conventional conditions such as the conditions described in the "Molecular Cloning Experiment Guide (4th Edition)" (Chinese version) published by Science Press, or according to the conditions recommended by the manufacturer. They are experimental operations well known to those skilled in the art, and the present invention is not limited thereto.

[0033] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0034] The present invention is based on sea frog ( Rana cancrivora) was used as the research object to dig out a polypeptide of Acinetobacter baumannii, referred to as polypeptide CDPEP-135. The amino acid sequence of polypeptide CDPEP-135 precursor includes 46 amino acids, its signal peptide contains 16 amino acids, and the mature peptide contains 30 amino acids (AKIPSSRLDDLHLAGVMTCRFLPIECKIKI), its molecular weight is 3367.11Da, its isoelectric point is 8.86, and the specific pairing mode of disulfide bond pairing is C19-C26.

[0035] The present invention constructs a recombinant plasmid CDPEP-135-pET32a by PCR technology, transforms Escherichia coli with the recombinant plasmid to achieve heterologous expression of polypeptide CDPEP-135, and then purifies the polypeptide CDPEP-135 produced by the recombinant strain through Ni NTA column.

[0036] The present invention can also obtain the polypeptide CDPEP-135 by chemical synthesis.

[0037] Example 1 Prokaryotic expression of polypeptide CDPEP-135.

[0038] The amino sequence of the peptide CDPEP-135 was optimized by online codon optimization software (https: / / www.novopro.cn / tools / codon-optimization.html), and the enterokinase cleavage site (GACGACGACGACAAG) and the termination codon (TAA) were added to the front and rear ends of the optimized nucleotide sequence encoding CDPEP-135, and EcoRI / HindIII restriction sites were added to the front and rear ends of the above nucleotide sequence. The above sequence was artificially synthesized (completed by Nanjing GenScript Biotechnology Co., Ltd.) and constructed into the pET32a vector through the EcoRI / HindIII restriction site. The constructed CDPEP-135-pET32a plasmid was transformed into BL21 (DE3) Escherichia coli, and a single clone was picked and inoculated in LB medium containing ampicillin resistance (ST007, Beyotime), and cultured at 37℃ 220 rpm for 6-8 hours, and 300 μL was aliquoted and sent to Qingke Biotechnology Co., Ltd. for sequencing, and the bacterial solution with correct sequencing was used for subsequent prokaryotic expression. The sequenced and revived bacterial suspension was inoculated into 1 L of LB medium containing resistance at a ratio of 1:100 and cultured in a shaking incubator at 37°C and 220 rpm. 600nmAfter the value reaches 0.6-0.8, add IPTG with a final concentration of 1 mM to induce polypeptide expression. Induce expression at 28°C and 100 rpm for 12-16 hours. After induction, collect the bacterial solution by centrifugation, wash twice with ultrapure water, and then centrifuge to remove the supernatant. Resuspend the bacteria with PBS until there is no obvious bacterial precipitation. Pour the bacterial solution into a homogenizer and break it continuously for 3 times to ensure that there is no obvious precipitation in the bacterial solution. Centrifuge to collect the supernatant of the bacterial solution.

[0039] Enzymatic digestion and separation and purification of peptide CDPEP-135: The supernatant sample of the pretreated bacterial solution was loaded onto the equilibrated nickel column, and the impurities were eluted with 10 mM and 30 mM imidazole solutions, and the target protein was eluted and collected with 300 mM imidazole solution. In a 25 mM Tris-HCl (pH8.0) system, 0.2 U enterokinase (P4237-1000U, Beyotime) was added for every 0.1 mg of Flag fusion protein for enzymatic digestion. The enzymatic digestion conditions were 25°C and the digestion lasted for 12-14 hours. After the bacterial cells were broken, the supernatant samples, the samples purified by the nickel column, and the samples after enzymatic digestion were subjected to SDS-PAGE electrophoresis analysis. After the analysis was completed, the peptide samples after enzymatic digestion were separated and purified by a self-assembled C18 reverse column. The specific conditions are as follows: the column is equilibrated with 0.1% TFA in 5% acetonitrile water, the sample after enzyme digestion is loaded onto the equilibrated column, desalting and washing are performed with 2 column volumes of 0.1% TFA in 5% acetonitrile water, and the target protein is eluted with one column volume of 0.1% TFA in 40% acetonitrile water to obtain the peptide CDPEP-135.

[0040] Example 2 Chemical synthesis of peptide CDPEP-135.

[0041] (1) Linear peptide synthesis Specific steps: Weigh 0.2 g of resin and place it in a dry and clean reaction tube, add an appropriate amount of N,N-dimethylacetamide (DMF), activate for 30 minutes, weigh 1 mmol of the first amino acid residue, 150 mg of 4-dimethylamino-pyridine (DMAP) and add them to the reaction tube, use DMF as solvent to react for 3 hours. After the reaction is completed, wash with DMF 3-6 times, add appropriate pyridine (Pyridine) and acetic anhydride (Acetic anhydride) in a volume ratio of 1:1, and react for 30 minutes. After the reaction is completed, wash with DMF 3-6 times. Then use piperidine to elute the amino acid's protective group Fmoc (9-fluorenylmethyloxycarbonyl), eluting twice for 15 minutes each time, then wash with DMF 4 times and methanol 2 times.

[0042] Weigh 3 mmol of the second amino acid and 3 mmol of O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluorophosphate (HBTU) in a reaction tube, add 0.5 ml of N,N-diisopropylethylamine (DIEA), react for 40 minutes, wash with DMF 3-6 times, add piperidine solution twice, each time for 10 minutes to elute the amino acid's protecting group Fmoc, then wash with DMF 4 times and methanol 2 times.

[0043] Repeat the second step until the last amino acid residue has reacted, cut with trifluoroacetic acid for 2 hours, filter the reaction to obtain a trifluoroacetic acid solution of the peptide, precipitate with ether, centrifuge, and wash with ether 3-5 times to obtain a white solid, desalt with HPLC, and freeze-dry to obtain a peptide sample.

[0044] (2) CDPEP-135 linear peptide renaturation (disulfide bond formation) CDPEP-135 contains a pair of disulfide bonds, and the redox method is used to allow the polypeptide to automatically fold into the correct spatial structure.

[0045] Weigh the purified linear peptide CDPEP-135 and dissolve it in deionized water. The final peptide concentration is 2 mg / mL. Add an equal volume of iodine in acetic acid solution (100 mL acetic acid contains 58 mg iodine) to the solution and react for 60 minutes. Add saturated ascorbic acid solution (100 mg ascorbic acid dissolved in 100 mL pure water containing 0.1% TFA) dropwise while stirring to turn the solution from yellow to colorless. Use semi-preparative RP-HPLC for separation and purification, and freeze-dry to obtain the target peptide CDPEP-135. Use analytical RP-HPLC and ESI-MS to monitor the renaturation process and identify the renaturation and purification samples.

[0046] Example 3 In vitro detection of the antibacterial activity of CDPEP-135 against Acinetobacter baumannii.

[0047] Acinetobacter baumannii (ATCC 27660, ATCC 6528, ATCC 25904, ATCC 25923, ATCC 29213, ATCC 49951) were purchased from Guangdong Microbiological Culture Collection Center; multidrug-resistant strains of Acinetobacter baumannii (NRS148, NRS103, NRS102, NRS112, NRS113, NRS123) were obtained in our laboratory by inducing ATCC 27660 strains with antibiotics (ceftazidime, imipenem, cefoperazone).

[0048] The frozen bacterial solution was taken out from the -80 ℃ refrigerator and thawed. The bacterial solution was diluted in a sterile clean bench, and the bacterial dilution was streaked on the NA (HB0109-4, Qingdao Haibo Biological) medium with an inoculation loop. The plate was inverted in an incubator and cultured at 37 ℃ for 16-20 h. A single colony was picked and inoculated into 100 mL MH broth medium (028040, Huankai), and cultured at 160 rpm and 37 ℃ in a constant temperature oscillator for 16-20 h.

[0049] Take the above logarithmic growth phase Acinetobacter baumannii culture liquid, centrifuge the culture liquid at 3000 g for 3 minutes, wash the culture medium three times, and then resuspend the culture liquid with fresh broth culture medium. Measure the OD of the bacterial suspension with a multifunctional microplate reader. 600nm Use fresh broth medium to dilute the bacterial solution to 2.0×10 5 CFU / mL, the diluted bacterial suspension was added to a 96-well plate, 100 μL was added to each well. Then the doubly diluted CDPEP-135 drug solution containing different concentrations was added to a sterile 96-well plate, 10 μL per well in wells 1 to 11, and the drug concentrations were 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, and 0.25 μg / mL, respectively. At the same time, 1 μg / mL of polymyxin (C114323-1g, Aladdin) was added as a positive control. After the bacterial solution was cultured for 24 hours, the absorbance value of the bacterial solution at 600 nm was measured using an ELISA reader (Epoch, BioTek). This experiment was repeated 3 times in parallel, and the average value was used for statistics.

[0050] The experimental results showed that CDPEP135 has a strong inhibitory activity against a variety of Acinetobacter baumannii, and its MIC value is 4-16 μg / ml (as shown in Table 1).

[0051] Table 1. Minimum inhibitory concentration (MIC) (μg / ml) of peptide CDPEP135 against 11 strains of Acinetobacter baumannii.

[0052]

[0053] Example 3 Effects of CDPEP-135 on the microstructure of Acinetobacter baumannii.

[0054] Scanning electron microscopy was used to observe the microscopic morphological changes of bacteria after CDPEP-135 treatment. The specific operation steps were as follows: the bacteria in the exponential growth phase were centrifuged at 5000 g for 5 minutes and the precipitate was collected, washed three times with sterile PBS solution, and the bacterial precipitate was collected and resuspended to OD 600nm = 0.2; 10 mL of the above bacterial solution was added to it, and the CDPEP-135 solution with a final concentration of 1×MIC was added to it, and it was cultured at 37°C for 30 minutes. The treatment group without peptide was used as a negative control; 4°C, 5000 g centrifugation for 5 minutes, the precipitate was collected, and 0.6 mL (pH=7.4) of 2.5% glutaraldehyde was added, and it was fixed at 4°C overnight; after washing with sterile PBS for 3 times, it was dehydrated with 50%, 70%, 90% and 100% ethanol gradient for 10 minutes respectively. Then, the samples were treated with pure ethanol, a 1:1 mixture of pure ethanol and tert-butanol, and pure tert-butanol for 15 minutes respectively. 0.6 mL of pure tert-butanol was added to dry and the film was plated. Finally, the surface morphology of the bacterial membrane was observed using a scanning electron microscope (TECNAI G2, BIOTWIN).

[0055] After treating Acinetobacter baumannii with CDPEP-135 at 1×MIC concentration for 30 minutes, the experimental results are as follows Figure 1 As shown, Acinetobacter baumannii showed bacterial body rupture and bacterial cell swelling.

[0056] Example 4 Hemolytic toxicity test of peptide CDPEP-135.

[0057] Select human blood cells, centrifuge at 4 °C and 500 g for 10 minutes, discard the supernatant, wash the lower layer of red blood cells three times with saline, and resuspend them into 3% red blood cell suspension. Add 100 μL of CDPEP-135 polypeptide solution of different concentrations to the EP tube. The final concentrations of the polypeptide solution in each tube are 512, 256, 128, 64, 32, 16, 4, and 2 μg / mL, respectively, and add 100 μL of red blood cell suspension. Three parallel groups were set up for each group. An equal volume of saline was added to the negative control group, and 100 μL of 0.1% TritonX-100 was added to the positive control group. The plate was placed in a biochemical incubator at 37 °C for 0.5 h, taken out, centrifuged at 500 g for 10 minutes, 100 μL of supernatant was transferred to a 96-well plate, and the absorbance at a wavelength of 570 nm was measured with an enzyme reader. The experiment was repeated three times, and the data obtained were averaged. Hemolysis rate = [(OD 试验孔 -OD 阴性孔 ) / (OD 阳性孔 -OD 阴性孔 )]×100%.

[0058] The experimental results are as follows Figure 2 As shown, the peptide CDPEP-135 had no obvious hemolytic activity below 64 μg / mL, that is, the hemolysis rate was less than 5%.

[0059] Example 5 In vivo detection of the antibacterial activity of peptide CDPEP-135 against Acinetobacter baumannii.

[0060] Balb / c mice, male, 6-8 weeks old, weighing 18-20 g, were purchased from Sichuan Weitong Lihua Experimental Animal Technology Co., Ltd. All mice were housed in a special pathogen-free (SPF) animal room with a temperature of 18-25 °C and a humidity of 50-70%, with alternating light and dark for 12 h. They were free to eat and drink sterile water. Before infection in this experiment, CTX (Cyclophosphamide, 50-18-0, Aladdin) was given to suppress immunity, and mice with only immunosuppression were used as the control group. Mice in each group were killed at 48 h after infection, and any deaths during the experiment were immediately dissected.

[0061] 1. Establishment of mouse lung infection model of Acinetobacter baumannii Mice that had adapted to the environment and were fed for 3 days were injected intraperitoneally with 3 mg CTX for 2 consecutive days, and then continued to be fed normally for 3 days. The mice were weighed daily and their status and mortality were observed. Except for the mice in the control group, the mice that had been fed for 3 days were anesthetized by intraperitoneal injection of Zoletil (Virbac) 1 mg / mouse. The anesthetized mice in each group were placed in a 30 cm × 15 cm × 20 cm sealed plastic box, and the neck of the mice was raised as much as possible to keep the mouse airway completely open. 9 The bacterial liquid (NRS148 strain) with CFU / mL was taken out from -4 ℃ and placed at room temperature for 15 minutes. After shaking, it was placed in the medicine cup of the ultrasonic nebulizer (small animal nebulizer drug delivery instrument, Beijing Yuansen Kaide Biotechnology Co., Ltd.). The nebulization tube was connected to the inlet in the plastic container, and the nebulized gas was discharged from the outlet. The residual nebulized gas was collected with activated carbon. The nebulizer was turned on at a nebulization speed of 2 mL / min. The nebulization was performed for 30 minutes, and then the mice were upright and rotated left and right to ensure that the nebulized liquid entered the lungs. Activated carbon was used to absorb the exhaust gas at the outlet of the nebulizer container. All operations were performed in a biological safety cabinet.

[0062] 2. Drug administration and efficacy evaluation in lung infection model mice After modeling, mice in the 2 mg / kg CDPEP-135 group, 4 mg / kg CDPEP-135 group, 8 mg / kg CDPEP-135 group, 4 mg / kg polymyxin group, and saline group were injected with drugs through the tail vein, with a volume of 100 μL per mouse. 48 hours after administration, all mice were killed by cervical dislocation (natural death mice were directly dissected), and the thorax was immediately opened, and the lung tissue of the mice was obtained under aseptic operation. The right main bronchus was ligated, and the alveolar lavage of the left lung was performed. 0.5 mL of sterile PBS was injected into the lung tissue and slowly rinsed 3 times, and the bronchoalveolar lavage fluid (BALF) was recovered, and the recovery rate was >80%. After lavage, the ligated right lung was divided into two parts and fixed in paraformaldehyde fixative. Cut the left lung into pieces and put it into a sterile glass tissue grinder. Add 2 mL PBS and grind it to make the bacteria completely enter the suspension. Filter it through a 70 μm pore filter membrane, dilute the suspension 10 times with sterile PBS, take 100 μL of each and inoculate it into a sterile blood plate. After evenly spreading it, place it in a 37 ℃ incubator and culture it for 18 h. Count the number of bacteria on the plate and finally calculate the number of bacteria in the lungs of each mouse.

[0063] The lung tissues fixed with paraformaldehyde were sectioned and stained with HE for pathological evaluation.

[0064] The experimental results show that Figure 3 As shown in the figure, infection of mouse lungs with drug-resistant Acinetobacter baumannii caused significant damage to the mouse lungs, and colistin sulfate (CS) had a certain therapeutic effect, but the therapeutic effect was relatively poor. After treatment with the antimicrobial peptide CDPEP135, 4 mg / kg had a relatively good effect, and 8 mg / kg basically returned to normal levels. like Figure 4 and Figure 5 As shown, the number of Acinetobacter baumannii and the number of inflammatory cells in the lungs were detected simultaneously. CDPEP135 reduced the number of bacteria in lung tissues in a concentration-dependent manner ( Figure 4 ) and the number of inflammatory cells ( Figure 5 ), that is, CDPEP135 effectively treats lung infections caused by Acinetobacter baumannii.

[0065] For matters not mentioned above, the prior art applies.

[0066] Although some specific embodiments of the present invention have been described in detail through examples, those skilled in the art should understand that the above examples are for illustration only and are not intended to limit the scope of the present invention. Those skilled in the art to which the present invention belongs may make various modifications or supplements to the specific embodiments described or replace them in a similar manner, but they will not deviate from the direction of the present invention or exceed the scope defined by the attached claims. Those skilled in the art should understand that any modifications, equivalent substitutions, improvements, etc. made to the above embodiments based on the technical essence of the present invention should be included in the protection scope of the present invention.

Claims

1. A polypeptide CDPEP-135, characterized in that: The polypeptide CDPEP-135 is specifically as follows A1) or A2): A1) The amino acid sequence is shown in SEQ ID NO.1; A2) A fusion protein obtained by connecting a tag to the N-terminus or / and C-terminus of A1).

2. The biomaterial related to the polypeptide CDPEP-135 according to claim 1, which is any one of the following B1) to B6): B1) a nucleic acid molecule encoding the polypeptide CDPEP-135 according to claim 1; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant microorganism containing the nucleic acid molecule described in B1); B5) a recombinant microorganism containing the expression cassette described in B2); B6) A recombinant microorganism containing the recombinant vector described in B3).

3. Use of the biomaterial according to claim 2 in the preparation of polypeptide CDPEP-135.

4. Use of the polypeptide CDPEP-135 according to claim 1 or the biomaterial according to claim 2 in the preparation of medicines against Acinetobacter baumannii and / or multidrug-resistant Acinetobacter baumannii.

5. The use according to claim 4, characterized in that The Acinetobacter baumannii is at least one of ATCC 27660, ATCC 6528, ATCC 25904, ATCC 25923, ATCC 29213 and ATCC 49951.

6. The use according to claim 4, characterized in that The multidrug-resistant Acinetobacter baumannii is a strain resistant to cephalosporins, carbapenems and aminoglycosides.

7. A pharmaceutical composition, characterized in that The invention comprises the polypeptide CDPEP-135 or a pharmaceutically acceptable salt thereof as claimed in claim 1, and pharmaceutical excipients.

8. The pharmaceutical composition according to claim 7, characterized in that The polypeptide CDPEP-135 is the only effective active ingredient.

9. Use of the polypeptide CDPEP-135 or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a medicament for treating or preventing infections and diseases caused by Acinetobacter baumannii.

10. The use according to claim 9, characterized in that The disease is one or more of ventilator-associated pneumonia, sepsis, urinary tract infection and wound infection.

Citation Information

Cited By

  • Polypeptide and application thereof

    CN120463776A

  • Polypeptides and uses thereof

    CN120463776B